EpiSign compleet – geen late onset

EpiSign compleet – geen late onset, is een uitgebreide analyse die meer dan 50 genen en aandoeningen (geen late onset) omvat die hieronder worden vermeld.Hierbij wordt gekeken naar zowel specifieke episignaturen als afwijkende methylatie bij imprinting diorders of bij repeat expansie syndromen (FraX). (NB: in de huidige versie v3 is alleen ADCADN (DNMT1) een late onset aandoening).

Afwijkingen die met behulp van deze screening worden gedetecteerd, kunnen aanvullende gerichte tests vereisen om de onderliggende genomische afwijking te identificeren en verder te karakteriseren.

Deze test kan een nuttige aanvullende test zijn voor patiënten met ontwikkelingsachterstand, of met een of meer overlappende kenmerken die wijzen op een van de weergegeven aandoeningen

Imprinting and Trinucleotide Repeat Disorders:
Angelman syndrome 15q11.2-q13 (SNRPN promoter, SNURF)
Beckwith-Wiedemann syndrome 11p15 (ICR1, KCNQ1OT1, CDKN1C)
Diabetes mellitus, transient neonatal 1 6q24 (PLAG1)
Fragile X syndrome FMR1
Kagami-Ogatta syndrome 14q32 (MEG3 promoter)
Mental retardation, FRA12A type (DIP2B promoter)
Mulchandani-Bhoj-Conlin syndrome 20q11-q13 (GNAS)
Prader-Willi syndrome 15q11.2 (SNRPN promoter, SNURF)
Pseudohypoparathyroidism, Type IA, IB 20q13.32 (GNAS)
Silver Russel syndrome 1 11p15 (ICR1)
Silver Russel syndrome 2 7p13-q32
Temple syndrome 14q32 (MEG3 promoter)

Episignatuur:
Alpha-thalassemia mental retardation syndrome (ATRX)
Arboleda-Tham syndrome (KAT6A)
Autism, susceptibility to, 18 (CHD8)
BAFopathies: Coffin-Siris 1-4 & Nicolaides-Baraitser syndromes ¹ (BAFopathy) (ARID1B, ARID1A, SMARCB1, SMARCA4, SMARCA2)
Beck-Fahrner syndrome ^2,3 (TET3)
Blepharophimosis Intellectual disability SMARCA2 syndrome (SMARCA2)
Börjeson-Forssman-Lehmann syndrome (PHF6)
CHARGE syndrome (CHD7)
Chr1p36 deletion syndrome, distal (Chr1p36 deletion)
BAFopathies: Coffin-Siris syndrome 1 and 2 ⁴ (ARID1B, ARID1A)
Coffin-Siris syndrome-1 ⁵ (ARID1B)
Coffin-Siris syndrome-2 ⁵ (ARID1A)
Coffin-Siris syndrome-3 ⁵ (SMARCB1)
Coffin-Siris syndrome-4 ⁵ (SMARCA4)
Coffin-Siris syndrome-4 ⁶ (CSS4_c.2656) (SMARCA4)
Coffin-Siris syndrome-9 (SOX11)
Congenital Heart Defects, Dysmorphic Facial Features, and Intellectual Developmental Disorder (CDK13, CCNK)
Cornelia de Lange syndromes 1-4 ⁷ (NIPBL, SMC1A, SMC3, RAD21)
Down syndrome (Chr21 trisomy)
Dystonia 28 (KMT2B)
Epileptic encephalopathy, childhood-onset (CHD2)
Floating Harbour syndrome (SRCAP)
Gabriele-de Vries syndrome (YY1)
Genitopatellar syndrome (see also Ohdo syndrome) ⁸ (KAT6B)
Helsmoortel-van der Aa syndrome ⁹ (ADNP)
Hunter McAlpine craniosynostosis syndrome (Chr5q35-qter duplication)
Immunodeficiency-centromeric instabilityfacial anomalies syndromes 1-4 ¹⁰ (DNMT3B, CDCA7, ZBTB24, HELLS (242860, 614069, 616910, 616911)
Intellectual developmental disorder with seizures and language delay (SETD1B)
Intellectual developmental disorder, X-linked 93 ² (BRWD3)
Intellectual developmental disorder, X-linked 97 (ZNF711)
Intellectual developmental disorder, X-linked, syndromic, Armfield type (FAM50A)
Intellectual developmental disorder, X-linked, syndromic, Claes-Jensen type ^2,11 (KDM5C)
Intellectual developmental disorder, X-linked syndromic, Nascimento-type ¹² (UBE2A)
Intellectual developmental disorder, X-linked, Snyder-Robinson type (SMS)
Kabuki syndrome 1 and 2 (KMT2D, KDM6A)
Kabuki syndrome 1 ¹³ (KMT2D)
Kabuki syndrome 2 ¹³ (KDM6A)
KBG Syndrome ¹⁴ (ANKRD11)
KDM2B-related syndrome (KDM2B)
Kleefstra syndrome 1 (EHMT1)
Klinefelter Syndrome (XXY)
Koolen de Vreis syndrome (KANSL1)
Luscan-Lumish syndrome (SETD2)
Menke-Hennekam syndrome 1 and 2 ¹⁵ (CREBBP, EP300) ID4 domains
Mental retardation, autosomal dominant 23 ¹⁴ (SETD5)
Mental retardation, autosomal dominant 51 ² (KMT5B)
Nicolaides-Baraitser syndrome ⁵ (SMARCA2)
Ohdo syndrome, SBBYSS variant (see also Genitopatellar syndrome) ⁸ (KAT6B)
Phelan-McDermid syndrome ¹⁶ (Chr22q13.3 deletion)
Potocki-Lupski syndrome (Chr17p11.2 duplication)
PRC2 Complex (Weaver syndrome and Cohen-Gibson syndrome) ¹⁷ (EED, EZH2)
Rahman syndrome (HIST1H1E)
Renpenning syndrome (PQBP1)
Rubinstein-Taybi syndrome 1 and 2 (CREBBP, EP300)
Rubinstein-Taybi syndrome 1 ¹⁸ (CREBBP)
Rubinstein-Taybi syndrome 2 ¹⁸ (EP300)
Sifrim-Hitz-Weiss yndrome (CHD4)
SLC32A1 related disorder (SLC32A1)
Smith-Magenis syndrome ¹⁹ (Chr17p11.2 deletion)
Sotos syndrome 1 (NSD1)
Tatton-Brown-Rahman syndrome (DNMT3A)
Velocardiofacial syndrome (Chr22q11.2 deletion)
White-Sutton syndrome (POGZ)
Wieacker-Wolff Syndrome (ZC4H2)
Wiedemann-Steiner syndrome (KMT2A)
Williams-Beuren syndrome (Chr7q11.23 deletion)
Williams-Beuren region duplication syndrome (Chr7q11.23 duplication)
Witteveen-Kolk syndrome (SIN3A)
Wolf-Hirschhorn syndrome ²⁰ (Chr4p16.13 deletion, NSD2)

^1. Patients with other BAFopathy genes may be detected, but not confirmed in our experiments.
^2. Healthy carriers and those with incomplete penetrance are detectable.
^3. Patients with biallelic variants are distinguishable from those with monoallelic variants.
^4. Only for variants near c.6200. No separate episignature due small cohort size, however these samples cluster separately from other BAFopathy/CSS1&2 samples.
^5. This is a secondary signature; sample must also be positive for BAFopathy signature.
^6. Only for variants at c.2656. No separate episignature due small cohort size however these samples cluster separately from other BAFopathy/CSS4 samples.
^7. Male CdLS5 patients (HDAC8 mutations) may be detected, but not confirmed in our experiments.
^8. GTPTS and SBBYSS are both caused by KAT6B mutations. We will report both regardless of which one is requested.
^9. ADNP consists of two distinct episignatures dependent on variant location. HVDAS_T includes variants within the N- and C-terminus while HVDAS_C includes variants within the central region (approximately c.2054-2340).
^10. ICF1 exhibits a unique episignature while ICF 2, 3 and 4 exhibit a distinct, shared episignature.
^11. Heterozygotes have a distinct profile from hemizygotes
^12. Carriers have not been detected in our experiments.
^13. This is a secondary signature; sample must also be positive for combined Kabuki signature.
^14. KBGS and MRD23 share a common episignature. Separate KGBS and MRD23 episignatures will be used as secondary signatures, with sample positivity for the combined KBGS/MRD23 episignature required.
^15. Only for domain ID4. MKHK1/2 exhibit a shared ID4 domain episignature and therefore cannot distinguish between MKHK1 and MKHK2. Other domains of MKHK1/2 are not available for assessment.
^16. Only for copy number variants. Sequence variants in SHANK3 have been shown to not match the episignature.
^17. Shared episignatures between PRC2 complex syndromes WVS and COGIS.
^18. This is secondary signature; sample must also be positive for combined RSTS signature.
¹⁹. Only for copy number variants. Sequence variants in RAI1 have been shown to not match the episignature.
^20. WHS episignature can detect truncating variants in NSD2.

The following list of genes have been classified as having reduced sensitivity and more moderate episignatures based on
episignature strength, limited reference cohort size, or types of mutations that have been tested: ANKRD11, BRWD3,
CCNK, CDCA7, CDK13, CHD8, DNMT1, DNMT3A, DNMT3B, FAM50A, HELLS, KAT6A, KAT6B, KMT5B, PHF6, PQBP1, SETD5,
SIN3A, SLC32A1, SOX11, SMS, UBE2A, YY1, ZBTB24, ZC4H2, ZNF711, Chr1p36del, Chr17p11.2dup.

Perifeer bloed verzameld in een EDTA-buis. Zie Voorwaarden aanvragen Laboratorium Genoomdiagnostiek voor algemene instructies.

Al geëxtraheerd DNA of opgeslagen DNA wordt ook geaccepteerd voor deze test, indien het oorspronkelijke monster volbloed was dat in een EDTA-buisje was verzameld (minimale hoeveelheid 5 ug).

Het monster moet bij kamertemperatuur worden bewaard en ‘s nachts worden verzonden.

Als de verzending een of twee dagen vertraging oploopt, moet het monster worden gekoeld en bij kamertemperatuur worden verzonden.

Vries het monster niet in. Op vrijdag verzamelde monsters kunnen veilig worden aangewezen voor levering op maandag.